MetaCap

Allogene Therapeutics (ALLO) vs Century Therapeutics (IPSC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Century Therapeutics (IPSC) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 137.8% versus a loss of 49.0%. Over five years, IPSC leads with a -93.2% price change compared with -96.5% for ALLO. Allogene Therapeutics is the larger company by market cap ($217.5 million vs $211.6 million), about 1.0 times the size, while Century Therapeutics is growing revenue faster (+1556.8% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLO-48.97%IPSC+137.76%
+527%+226%-76%
Nov 21, 20251 yearNov 20, 2026
ALLO-96.66%IPSC-94.35%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLO versus IPSC key metrics
MetricALLOIPSC
Share price$0.6277$1.17
Market cap$217.48M$211.56M
1-day change-5.88%-11.74%
YTD return-54.18%+17.09%
1-year return-48.97%+137.76%
5-year return-96.51%-93.23%
EPS (TTM)$-0.61$-0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$109.16M
Revenue growth (YoY)-100.00%+1556.76%
Net income (latest FY)$-190.89M$-9.58M
Operating margin—-15.82%
Net margin—-8.78%
52-week high$4.46$3.04
52-week low$0.6192$0.48
Distance from 52-week high-85.93%-61.68%
Analyst consensusstrong_buybuy
Avg. price target upside+1333.81%+307.73%
Average volume7.69M759.69K
Shares outstanding346.47M181.60M
Employees15078
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IPSC has outperformed ALLO by 186.7 percentage points over the past year.
  • Century Therapeutics grew revenue faster in its latest fiscal year (+1556.76% vs -100.00%).

About Allogene Therapeutics

ALLO stock →

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees

About Century Therapeutics

IPSC stock →

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees

ALLO vs IPSC FAQ

Which is bigger, Allogene Therapeutics or Century Therapeutics?

Allogene Therapeutics (ALLO) is larger, with a market capitalization of $217.48M compared with $211.56M for Century Therapeutics (IPSC).

Which stock has performed better over the past year, ALLO or IPSC?

IPSC returned +137.76% over the past 12 months, compared with -48.97% for ALLO (price return, excluding dividends). Past performance does not predict future results.

Are Allogene Therapeutics and Century Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons